Open AccessBenefit of Olaparib for BRCA-Mutated Advanced Ovarian Cancer
Author(s) -
Catlin Nalley
Publication year - 2020
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000723552.86174.ff
Subject(s) - olaparib , medicine , ovarian cancer , oncology , brca mutation , placebo , cancer , chemotherapy , parp inhibitor , progression free survival , pathology , alternative medicine , polymerase , poly adp ribose polymerase , gene , biochemistry , chemistry